LUNG.US Pulmonx Corp

Healthcare Health Care Equipment & Supplies USA Stocks
2.80 USD
Close of Nov 16, 2026
1.13 3.25
Market cap
USD 122M
P/E
-
P/B
3.63x
ROE
-125.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LUNG.US undervalued?

Graham number

The Graham number of Pulmonx Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pulmonx Corp fundamental analysis

No fundamental analysis for Pulmonx Corp yet.

Pulmonx Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pulmonx Corp

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative …

Full company profile